LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
23.83 32.26 0.00 0.00

+8 more quarters

P/S ratio
3.07 2.42 2.42 2.12
P/FCF ratio
29.69 21.07 18.94 15.21
P/Operating CF
67.88 228.44 40.73 33.64
P/B ratio
3.41 2.87 2.80 2.47
EV/Sales
2.92 2.25 2.23 1.96
EV/EBITDA
15.76 11.73 10.98 9.65
EV/FCF
28.23 19.54 17.48 14.08
Current Ratio
1.45 1.33 1.36 1.33
Net Debt/EBITDA
(3.07) (4.07) (4.10) (2.82)
Debt/Equity
0.22 0.24 0.31 0.38
Earnings Yield
4.20% 3.10% (7.23%) (7.62%)
Free Cash Flow Yield
3.37% 4.75% 5.28% 6.58%
Free Cash Flow per Share
0.64 0.02 1.05 1.14
Book value per Share
24.11 22.15 22.00 21.18
Free Cash Flow
35.04 0.93 57.45 62.18
EV/EBIT
22.91 16.77 15.53 13.67
Other line items

Show all line items

Columns are period end dates